Further, KRAS and c-MYC cooperate to drive an immunosuppressive TME in cancer development, leading to increase in macrophage infiltration of tumours and decrease in CD3+ T cells, B cells and natural killer (NK) cells. Here, MYC is linked to neoplasm.